Ocuphire Pharma Files 8-K on Operations and Financials
Ticker: IRD · Form: 8-K · Filed: May 10, 2024 · CIK: 1228627
Sentiment: neutral
Topics: operations, financials, disclosure
Related Tickers: OCUP
TL;DR
OCUP filed an 8-K detailing financial results and operations.
AI Summary
Ocuphire Pharma, Inc. filed an 8-K on May 10, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, formerly known as Rexahn Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Farmington Hills, MI.
Why It Matters
This 8-K filing provides crucial updates on Ocuphire Pharma's operational and financial status, which can impact investor decisions and market perception.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Ocuphire Pharma, Inc. (company) — Registrant
- Rexahn Pharmaceuticals, Inc. (company) — Former company name
- May 10, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Farmington Hills, MI (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Ocuphire Pharma, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as to include Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on May 10, 2024.
What was Ocuphire Pharma, Inc.'s former company name?
Ocuphire Pharma, Inc.'s former company name was Rexahn Pharmaceuticals, Inc.
In which state is Ocuphire Pharma, Inc. incorporated?
Ocuphire Pharma, Inc. is incorporated in Delaware.
What is the address of Ocuphire Pharma, Inc.'s principal executive offices?
The address of Ocuphire Pharma, Inc.'s principal executive offices is 37000 Grand River Avenue, Suite 120, Farmington Hills, MI 48335.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-10 08:12:11
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share OCUP The Nasdaq
Filing Documents
- ef20028807_8k.htm (8-K) — 28KB
- ef20028807_ex99-1.htm (EX-99.1) — 142KB
- image00001.jpg (GRAPHIC) — 5KB
- 0001140361-24-025329.txt ( ) — 323KB
- ocup-20240510.xsd (EX-101.SCH) — 4KB
- ocup-20240510_lab.xml (EX-101.LAB) — 21KB
- ocup-20240510_pre.xml (EX-101.PRE) — 16KB
- ef20028807_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On May 10, 2024, Ocuphire Pharma, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated May 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 10, 2024 OCUPHIRE PHARMA, INC. By: /s/ Dr. George Magrath Name: Dr. George Magrath Title: Chief Executive Officer